In-Vitro Diagnostics Should Be Eligible For Third-Party Review - Industry
This article was originally published in The Gray Sheet
Executive Summary
FDA should identify more in-vitro diagnostics for inclusion in the agency's "Accredited Persons" third-party premarket review program, DiaSorin VP Regulatory Affairs and Quality Systems, Judith Smith recommended.